PMID: 2494664Apr 1, 1989Paper

Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B

Proceedings of the National Academy of Sciences of the United States of America
L OsbornG J Nabel

Abstract

Binding of peptide hormones to surface membrane receptors leads to the transcription of specific genes within relevant target cells. How these signals are transduced to alter gene expression is largely unknown, but this mechanism probably involves a sequence of enzymatic steps that activate factors in the nucleus that modulate transcription. We now demonstrate that two different peptide hormones, or cytokines, stimulate the human immunodeficiency virus enhancer, and this effect is mediated by nuclear factor (NF) kappa B (nuclear factor that binds the kappa immunoglobulin light chain gene enhancer). These cytokines, tumor necrosis factor alpha and interleukin 1, act on multiple cell types and represent the only naturally occurring activators of this transcription factor among eight cytokines examined. Although NF-kappa B binding can be stimulated by phorbol 12-myristate 13-acetate, tumor necrosis factor alpha acts through an independent mechanism, inducing NF-kappa B binding in HT-2 cells, which did not show increased binding in response to phorbol 12-myristate 13-acetate, and causing superinduction in Jurkat T-lymphoma cells. Tumor necrosis factor alpha is also a more selective activator of T cells than phorbol 12-myristate 13-...Continue Reading

References

Jun 9, 1988·The New England Journal of Medicine·H R MichieD W Wilmore
Jul 11, 1986·Science·S GartnerM Popovic
May 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G J NabelD Baltimore
Oct 28, 1988·Science·P A Baeuerle, D Baltimore
Feb 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A S Baldwin, P A Sharp
Feb 12, 1987·The New England Journal of Medicine·B Beutler, A Cerami
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A IsraëlP Kourilsky
Oct 30, 1986·Virology·S HaradaN Yamamoto

❮ Previous
Next ❯

Citations

Jun 19, 1998·Journal of Cellular Biochemistry·K E DolterJ Yu
Jan 7, 2000·Journal of Cellular Physiology·T IkebeK Shirasuna
Apr 1, 1992·Journal of Cellular Biochemistry·S C WrightJ W Larrick
May 16, 2002·Journal of Cellular Physiology·Thersa M SweetKamel Khalili
Dec 18, 2001·Journal of Medical Virology·M Di StefanoG Angarano
Nov 1, 1995·Medicinal Research Reviews·J Pallarés-TrujilloJ M Argilés
Jul 1, 1990·Virus Genes·N KobayashiN Yamamoto
Nov 1, 1995·Journal of Clinical Immunology·I SekigawaN Yamamoto
Jan 1, 1990·Biotherapy·D H Schwartz, T C Merigan
Jan 1, 1997·Journal of Biomedical Science·P.S. KedarS.L. Zeichner
Jan 1, 1995·International Journal of Clinical & Laboratory Research·N Yamamoto
Jun 29, 2006·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·José M Rodríguez-LópezClemente Muriel
Jul 11, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·R HemalathaB Sesikeran
Feb 27, 2008·Annals of Biomedical Engineering·Julie Y JiScott L Diamond
Dec 15, 2012·Apoptosis : an International Journal on Programmed Cell Death·Claudia FioriniMassimo Donadelli
Jan 30, 2013·Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu·Hui Yu
Jan 27, 1990·Lancet
Nov 1, 1995·Immunopharmacology·A KruseB K Pedersen

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.